IL-1 cytokines in cardiovascular disease: Diagnostic, prognostic and therapeutic implications
Date
2008Sujet
Résumé
Interleukins (ILs) are key mediators in the chronic vascular inflammatory response underlying several aspects of cardiovascular disease. Due to their powerful pro-inflammatory potential, and the fact that they are highly expressed by almost all cell types actively implicated in atherosclerosis, members of the IL-I cytokine family were the first to be investigated in the field of vessel wall inflammation. The IL-1 family is comprised of five proteins that share considerable sequence homology: IL-1α, IL-1β, IL-1 receptor antagonist (IL-1Ra), IL-18 (also known as IFNγ-inducing factor), and the newly discovered ligand of the ST2L receptor, IL-33. Expression of IL-1s and their receptors has been demonstrated in atheromatous tissue, and serum levels of IL-1-cytokines have been correlated with various aspects of cardiovascular disease and their outcome. In vitro studies have confirmed pro-atherogenic properties of IL-1α, IL-1β and IL-18 such as, upregulation of endothelial adhesion molecules, the activation of macrophages and smooth muscle cell proliferation. In contrast with this, IL-1Ra, a natural antagonist of IL-1, possesses anti-inflammatory properties, mainly through the endogenous inhibition of IL-1 signaling. IL-33 was identified as a functional ligand of the, till recently, orphan receptor, ST2L. IL-33/ST2L signaling has been reported as a mechanically activated, cardioprotective paracrine system triggered by myocardial overload. As the roles of individual members of the IL-1 family are being revealed, novel therapies aimed at the modulation of interleukin function in several aspects of cardiovascular disease, are being proposed. Several approaches have produced promising results. However, none of these approaches has yet been applied in clinical practice. © 2008 Bentham Science Publishers Ltd.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
Vasileiadis G.K., Dardiotis E., Mavropoulos A., Tsouris Z., Tsimourtou V., Bogdanos D.P., Sakkas L.I., Hadjigeorgiou G.M. (2018)Current clinical experience with immunomodulatory agents and monoclonal antibodies in principle has established the benefit of depleting lymphocytic populations in relapsing–remitting multiple sclerosis (RRMS). B and T ... -
IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFNγ-producing T cells
Mavropoulos A., Varna A., Zafiriou E., Liaskos C., Alexiou I., Roussaki-Schulze A., Vlychou M., Katsiari C., Bogdanos D.P., Sakkas L.I. (2017)Our aim was to study CD19(+)CD27(+)CD24(high) memory and CD19(+)CD24(high)CD38(high) transitional and IL-10 + Breg cells, known to inhibit Th1 and Th17 cells in experimental arthritis, in psoriatic arthritis (PsA) and ... -
A systematic review and meta-analysis of genetic association studies for the role of inflammation and the immune system in diabetic nephropathy
Tziastoudi M., Stefanidis I., Hadjigeorgiou G.M., Stravodimos K., Zintzaras E. (2017)Background: Despite the certain contribution of metabolic and haemodynamic factors in diabetic nephropathy (DN), many lines of evidence highlight the role of immunologic and inflammatory mechanisms. To elucidate the ...